These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 23161513)

  • 1. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.
    Demory Beckler M; Higginbotham JN; Franklin JL; Ham AJ; Halvey PJ; Imasuen IE; Whitwell C; Li M; Liebler DC; Coffey RJ
    Mol Cell Proteomics; 2013 Feb; 12(2):343-55. PubMed ID: 23161513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes.
    Dou Y; Cha DJ; Franklin JL; Higginbotham JN; Jeppesen DK; Weaver AM; Prasad N; Levy S; Coffey RJ; Patton JG; Zhang B
    Sci Rep; 2016 Nov; 6():37982. PubMed ID: 27892494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression.
    Shang A; Gu C; Zhou C; Yang Y; Chen C; Zeng B; Wu J; Lu W; Wang W; Sun Z; Li D
    Cell Commun Signal; 2020 Mar; 18(1):52. PubMed ID: 32228650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
    Lin YL; Liau JY; Yu SC; Ou DL; Lin LI; Tseng LH; Chang YL; Yeh KH; Cheng AL
    PLoS One; 2012; 7(11):e50701. PubMed ID: 23209813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
    Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
    Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples.
    Halvey PJ; Ferrone CR; Liebler DC
    J Proteome Res; 2012 Jul; 11(7):3908-13. PubMed ID: 22671702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
    Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
    PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.
    Kikuchi H; Pino MS; Zeng M; Shirasawa S; Chung DC
    Cancer Res; 2009 Nov; 69(21):8499-506. PubMed ID: 19843849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
    Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
    Singh A; Sweeney MF; Yu M; Burger A; Greninger P; Benes C; Haber DA; Settleman J
    Cell; 2012 Feb; 148(4):639-50. PubMed ID: 22341439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS.
    Guha U; Chaerkady R; Marimuthu A; Patterson AS; Kashyap MK; Harsha HC; Sato M; Bader JS; Lash AE; Minna JD; Pandey A; Varmus HE
    Proc Natl Acad Sci U S A; 2008 Sep; 105(37):14112-7. PubMed ID: 18776048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
    Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
    Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
    J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.
    Brandi G; Tavolari S; De Rosa F; Di Girolamo S; Agostini V; Barbera MA; Frega G; Biasco G
    PLoS One; 2012; 7(7):e41347. PubMed ID: 22911782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphiregulin exosomes increase cancer cell invasion.
    Higginbotham JN; Demory Beckler M; Gephart JD; Franklin JL; Bogatcheva G; Kremers GJ; Piston DW; Ayers GD; McConnell RE; Tyska MJ; Coffey RJ
    Curr Biol; 2011 May; 21(9):779-86. PubMed ID: 21514161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.